| Business Summary | | Synaptic
Pharmaceutical
Corporation
is
a
biotechnology
company
engaged
in
the
development
of
a
broad
platform
of
enabling
technology
that
it
calls
"human
receptor-targeted
drug
design
technology."
The
Company
is
utilizing
this
technology
in
its
genomics
program
to
discover
and
clone
the
genes
that
code
for
human
receptors.
The
Company
and
its
licensees
are
also
utilizing
this
technology
in
functional
genomics
programs
to
discover
the
function
of
these
receptors
in
the
body
and
thus
specific
physiological
disorders
with
which
they
may
be
associated.
Synaptic
and
its
licensees
are,
in
turn,
utilizing
the
cloned
receptor
genes
to
design
compounds
that
can
potentially
be
developed
as
drugs
for
treating
these
disorders.
In
line
with
this,
the
Company
has
implemented
several
programs
that
include
genomics
and
functional
genomics
research,
galanin
program,
NPY
program,
alpha
1a
antagonist
program
and
other
joint
research
programs. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | SNAP
is
a
biotechnology
company
engaged
in
the
development
of
a
broad
platform
of
enabling
technology,
called
``human
receptor-targeted
drug
design
technology'',
that
can
be
used
to
discover
and
clone
genes
used
in
treating
specific
disorders.
For
the
six
months
ended
6/30/01,
revenues
rose
31%
to
$743
thousand.
Net
loss
rose
27%
to
$9.9
million.
Results
reflect
the
proceeds
from
the
Kissei
agreement,
offset
by
increased
pre-clinical
testing
related
costs. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Kathleen Mullinix, Ph.D., 57 Chairman,
Pres, CEO | $385K | $421K | Robert Spence, 54 Sr.
VP, CFO and Treasurer | 210K | -- | Theresa Branchek, Ph.D., 47 VP
of Research | 251K | -- | Richard Weinshank, Ph.D., 44 VP
of Bus. Devel. | 223K | 173K | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|